



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : R. Vanlalsama, (Assistant Director (P and D))
CMO Office, Lunglei.
- Serial No. and date of Inspector's memorandum : 8 , 23-JAN-2026
- Number of Sample : MS-3
- Date of receipt : 25-FEB-2026
- Names of drugs purporting to be contained in the sample : Lcevocetirizine & Montelukast Tablets IP (EZEMONK-LC)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-GUW/LS/2026-26/1378	27/70	TG25-0632P	Apr-2025 Mar-2027	NA	Athens Life Sciences, Mauza Rampur, Jattan, Nahan Road, Kala Amb, Distt. Sirmour, H.P. -173030

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 27-Apr-2026 To 06-May-2026

COMPOSITION : Each film coated tablet contains:
Levocetirizine Hydrochloride IP 5 mg.
Montelukast Sodium Ip eq. to Montelukast 10 mg.

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, round, slightly bi-convex, film coated tablets, in alu-alu pack.	NA
2	Identification	Gives positive test for Levocetirizine Hydrochloride and Montelukast Sodium.	NA
3	Average weight	0.1125 g	NA
4	Dissolution	Complies for Montelukast and Levocetirizine HCl.	NLT 70 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
-------	-----------------	-------	-------	------------	--------	--------------------

1	Levocetirizine Hydrochloride	4.8 mg/Tablet	5 mg/Tablet	96	90 % to 110 %	I.P. 2022
2	Montelukast Sodium eq. to montelukast	9.53 mg/Tablet	10 mg/Tablet	95.3	90 % to 110 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 11-MAY-2026

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

-----END OF REPORT-----

